Skip to content

Study · Randomized controlled trial · n = 55 · 2020

3 results

Intranasal oxytocin attenuates insula activity in response to dynamic angry faces.

Ma Y, Ran G, Hu N, Hu Y, Long W, Chen X

Biological psychology4 Nov 2020Cited by 5 (Europe PMC)

PMID33157152 (opens in a new tab)DOI10.1016/j.biopsycho.2020.107976 (opens in a new tab)PepBankPUB-33157152
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants, intranasal oxytocin attenuated insula activation during the viewing of dynamic angry faces compared with placebo.

    In plain wordsIn people, nasal oxytocin reduced insula brain activity while viewing moving angry faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseInsula activation during dynamic angry faces
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    The results indicated that oxytocin attenuated activation of insula and emotional processing-related regions (e.g., ACC, thalamus, and MFG) during the viewing of dynamic angry faces.
    1 context sentence
    Summary · context
    Using a between-group, double-blind, placebo-controlled design, 55 participants were randomly assigned to groups receiving a single dose of 24 IU oxytocin or a placebo via intranasal administration.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants, intranasal oxytocin attenuated activation of emotional processing-related regions such as the ACC, thalamus and MFG during the viewing of dynamic angry faces compared with placebo.

    In plain wordsIn people, nasal oxytocin reduced activity in brain areas for processing emotion while viewing moving angry faces compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseActivation of ACC, thalamus and MFG during dynamic angry faces
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    The results indicated that oxytocin attenuated activation of insula and emotional processing-related regions (e.g., ACC, thalamus, and MFG) during the viewing of dynamic angry faces.
    1 context sentence
    Summary · context
    Using a between-group, double-blind, placebo-controlled design, 55 participants were randomly assigned to groups receiving a single dose of 24 IU oxytocin or a placebo via intranasal administration.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants, functional connectivity between the regions involved in perceiving dynamic angry faces was not changed by intranasal oxytocin compared with placebo.

    In plain wordsIn people, nasal oxytocin did not change how connected the brain areas for viewing angry faces were compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeFunctional connectivity between regions during dynamic angry faces
    Study

    n = 55

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    However, functional connectivity between the regions involved in the perception of dynamic angry faces was not changed following oxytocin administration.
    1 context sentence
    Summary · context
    Using a between-group, double-blind, placebo-controlled design, 55 participants were randomly assigned to groups receiving a single dose of 24 IU oxytocin or a placebo via intranasal administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.